Modifier genes and sickle cell anemia

Current Opinion in Hematology

Volumn 13, Issue 3, 2006, Pages 131-136

  Steinberg, Martin H ^a,b   Adewoye, Adeboye H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Fetal hemoglobin; Genetic association; Linkage disequilibrium; Single nucleotide polymorphisms; Transforming growth factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HEMOGLOBIN F; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

ACUTE CHEST SYNDROME; ALPHA THALASSEMIA; BONE NECROSIS; CASE CONTROL STUDY; CELL ADHESION; CELL INTERACTION; CHOLELITHIASIS; DISEASE COURSE; DNA MODIFICATION; ENVIRONMENTAL FACTOR; GENE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC EPISTASIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN GENOME PROJECT; INFECTION; INFLAMMATION; KLOTHO GENE; MODIFIER GENE; NONHUMAN; PAIN; PHENOTYPE; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; STROKE;

ANEMIA, SICKLE CELL; ANIMALS; GENETIC VARIATION; GENOTYPE; HUMANS; PHENOTYPE; POINT MUTATION; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 33646764967     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000219656.50291.73     Document Type: Review

References (57)

1. Nagel RL, Labie D. DNA haplotypes and the beta s globin gene. [review] Prog Clin Biol Res 1989; 316B:371-393.
2. Steinberg MH, Hsu H, Nagel RL, et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hematol 1995; 48:175-181.
3. Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 2003; 72:121-126.
4. Garner CP, Tatu T, Best S, et al. Evidence of genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am J Hum Genet 2002; 70:793-799.
5. Chang YC, Smith KD, Moore RD, et al. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotypes, α-globin gene number, gender, and age. Blood 1995; 85:1111-1117.
6. Garner C, Mitchell J, Hatzis T, et al. Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am J Hum Genet 1998; 62:1468-1474.
7. Garner C, Silver N, Best S, et al. A quantitative trait locus on chromosome 8q influences the switch from fetal to adult hemoglobin. Blood 2004; 104:2184-2186.
8. Close J, Game L, Clark B, et al. Genome annotation of a 1.5 Mb region of human chromosome 6q23 encompassing a quantitative trait locus for fetal hemoglobin expression in adults. BMC Genomics 2004; 5:33.
9. Wyszynski DF, Baldwin CT, Cleves MA, et al. Polymorphisms near a chromosome 6q QTL area are associated with modulation of fetal hemoglobin levels in sickle cell anemia. Cell Mol Biol 2004; 50:23-33.
10. Gardner C, Robas N, Cawkill D, Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000; 272:186-192.
11. Inoue A, Kuroyanagi Y, Terui K, et al. Negative regulation of gamma-globin gene expression by cyclic AMP-dependent pathway in erythroid cells. Exp Hematol 2004; 32:244-253.
12. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A 2001; 98:1847-1852.
13. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha(+)-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253-1257. This novel observation suggests that the interaction of two genes affecting the erythrocyte can have antagonistic effects, canceling the 'benefit' afforded by either gene acting alone.
14. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129:465-481.
15. Driscoll MC, Hurlet A, Styles L, et al. Stroke risk in siblings with sickle cell anemia. Blood 2003; 101:2401-2404.
16. Hoppe C, Klitz W, Noble J, et al. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 2002; 101:2865-2869.
17. Styles LA, Hoppe C, Klitz W, et al. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 2000; 95:3562-3567.
18. Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 2004; 103:2391-2396.
19. Taylor JG, Tang DC, Savage SA, et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002; 100:4303-4309.
20. Tang DC, Prauner R, Liu W, et al. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol 2001; 68:164-169.
21. Romana M, Diara JP, Doumbo L, et al. Angiotensinogen gene associated polymorphisms and risk of stroke in sickle cell anemia: additional data supporting an association. Am J Hematol 2004; 76:310-311.
22. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37:435-440. A novel method of modeling genetic interactions has high predictive value for forecasting the likelihood of having a stroke. The future may see similar approaches used for complication-specific approaches to screening and treatment.
23. Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 2005; 102:1661-1666. This work supports the contention that erectile function is modulated by genes regulating the nitric oxide pathway.
24. Nolan VG, Baldwin CT, Ma Q-L, et al. Association of single nucleotide polymorphisms in KLOTHO with priapism in sickle cell anemia. Br J Haematol 2004; 128:266-272.
25. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106:3264-3267. Hemolysis underlies the likelihood of developing priapism and suggests that means of reducing the hemolytic rate may be therapeutically useful.
26. Kutlar F, Tural C, Park D, et al. MTHFR (5, 10- methlylenetetrathydrofolate reductase) 677 C->T mutation as a candidate risk factor for avascular necrosis (AVN) in patients with sickle cell disease. Blood 1998; 92:695a.
27. DeCastro L, Rinder HM, Howe JG, Smith BR. Thrombophilic genotypes do not adversely affect the course of sickle cell disease (SCD). Blood 1998; 92:161a.
28. Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 1998; 59:267-272.
29. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002; 33:1037-1043.
30. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101: 1257-1261.
31. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-895.
32. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003; 92:1162-1169.
33. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277-280.
34. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68:92-102.
35. Ashley-Koch A, DeCastro L, Lennon-Graham F, et al. Genetic polymorphisms associated with the risk for pulmonary hypertension and proteinuria in sickle cell disease. Blood 2004; 104:464a.
36. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004; 36:707-717.
37. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653-1662.
38. Sharan K, Surrey S, Ballas S, et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 2004; 124:240-243.
39. Grasemann H, Ratjen F. Gender-specific disease modification by NOS3. Br J Haematol 2004; 126:160.
40. Grasemann H, Storm van's GK, Buscher R, et al. Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. Am J Respir Crit Care Med 2003; 167:1113-1116.
41. Grasemann H, Storm van's GK, Buscher R, et al. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167:390-394.
42. Sullivan KJ, Kissoon N, Duckworth LJ, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 2001; 164:2186-2190.
43. Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005; 2:423-433.
44. Lammert F, Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5:163-170.
45. Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 2005; 129:718-734.
46. Wang HH, Wang DQ. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology 2005; 42:894-904.
47. Passon RG, Howard TA, Zimmerman SA, et al. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001; 23:448-451.
48. Fertrin KY, Melo MB, Assis AM, et al. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clin Genet 2003; 64:160-162.
49. Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005; 105:968-972.
50. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med 2003; 141:279-282.
51. Nolan VG, Rybicki AC, Cohen HT, et al. Creatinine clearance in sickle cell anemia is modulated by genes in the TGF-β/BMP pathway. Blood 2005;106:877a.
52. Zennadi R, Hines PC, De Castro LM, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004; 104:3774-3781.
53. Eyler CE, Jackson TL, DeCastro L, et al. Effects of single nucleotide polymorphisms of the β2 adrenergic receptor and of adenylate cyclase on sickle red cell adhesion to laminin [abstract]. Blood 2004; 104:969a.
54. Tamouza R, Neonato MG, Busson M, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol 2002; 63:194-199.
55. Costa RN, Conran N, Albuquerque DM, et al. Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia. Haematologica 2005; 90:977-979.
56. Castro V, Alberto FL, Costa RN, et al. Polymorphism of the human platelet antigen-5 system is a risk factor for occlusive vascular complications in patients with sickle cell anemia. Vox Sang 2004; 87:118-123.
57. Nolan VG, Wilcox MA, Sebastiani P, et al. Gene-gene interactions and the pathophysiology of sickle cell disease: modeling the effects of SNPs on sickle cell-associated vasoocclusive events using classification and regression trees and stochastic gradient boosting. Blood 2005; 106:889a.